RegenxBio, Penn Sue Sarepta for Gene-Therapy Patent Royalties

RegenxBio and the University of Pennsylvania said Sarepta’s gene therapies for two types of muscular dystrophy infringe a patent for the use of a cultured host-cell technology in making medical treatments.

• RegenxBio and Penn are seeking cash compensation of at least a reasonable royalty and a court order blocking further unauthorized use of the invention until the patent has expired, according to complaint filed Tuesday in federal court in Wilmington, Delaware
• RegenxBio sells the competing NAV technology platform, which practices the patent and helps in the development of treatments for diseases “with significant unmet needs,” complaint says, “such as ...